3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Breast Neoplasms
15
Ovarian Neoplasms
9
Recurrence
3
Multiple Myeloma
3
Lymphoma, Large B-Cell, Diffuse
3
Neoplasms
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Non-Hodgkin
2
Carcinoma, Ovarian Epithelial
2
Uterine Cervical Neoplasms
1
Unrecognized Condition
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasm Epithelial
1
Muscle Invasive Bladder Cancer
1
Mesothelioma, Malignant
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Leukemia, Plasma Cell
1
Hodgkin Disease
1
HER2-positive Breast Cancer
1
Genetic Predisposition to Disease
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Advanced Solid Tumors
1
Advanced Breast Cancer
1
Interventions
Dexamethasone
2
liposomal doxorubicin
1
fludarabine phosphate
1
fludarabine
1
Melphalan
1
Maintenance
1
Calcium Dobesilate
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Leukemia, Plasma Cell
×
liposomal doxorubicin
×
Clear all
NCT01328236
2011-09-22
Bortezomib
Clinical Service, China
Phase 2
Unknown
20 enrolled